Left ventricular assist devices reduced the risk for death and increased 1-year survival in chronic end-stage heart failure
- Blood pumps for circulatory support. Reul, H.M.; Akdis, M. // Perfusion;Jul2000, Vol. 15 Issue 4, p295
Deals with mechanical blood pump systems as therapeutic instruments for the treatment of cardiac insufficiency. General blood pump classification; Clinical use and indications; Existing pump systems and current developments as of 2000; General design considerations.
- Partitioning device linked to positive long-term HF outcomes. // Cardiology Today;Oct2012, Vol. 15 Issue 10, p21
The article focuses on a study which revealed that a novel, minimally invasive device designed to separate healthy and damaged heart muscle and restore ventricular function improved, outcomes at 3 years in ischemic heart failure (HF) patients, presented at the 2012 European Society of Cardiology...
- `Managing' a disease may cut down on hospital stays. Bowser, Andrew // New Orleans CityBusiness (1994 to 2008);11/25/96, Vol. 17 Issue 21, p33
Focuses on managing a disease as a means of cutting down on hospital stays. Views of cardiologist Lester Ducote; Reason some patients get worse when they are released from hospital; Description of a program created by Ducote's medical practice; Information on managing congestive heart failure.
- Human growth hormone--better than we thought. Douglass, William Campbel // Second Opinion;Oct97, Vol. 7 Issue 10, p6
Highlights the reports of doctors at the University of Western Australia that human growth hormone (GHG) is effective in the treatment of severe heart failure. Case of two patients in severe heart failure who were treated with HGH; Possibility of a giant step forward in life extension.
- Heart failure patients should receive digoxin as first-line treatment. // Geriatrics;Sep97, Vol. 52 Issue 9, p25
Recommends the use of digoxin as medical treatment for patients with symptomatic congestive heart failure. Research that proved the efficacy of digoxin.
- Continuing digoxin therapy in patients with stable CHF is cost-effective. // Formulary;Oct95, Vol. 30 Issue 10, p621
Presents an abstract of the medical study `Economic Outcomes of Withdrawal of Digoxin Therapy in Adult Patients With Stable Congestive Heart Failure,' by R.E. Ward, J.B. Young et al, published in the Journal of American College Cardiology 1995.
- Medtronic trumps rival, aids patients, as analysts sing praises of new InSync pacer. Lillis, Karin // Healthcare Purchasing News;Oct2001, Vol. 25 Issue 10, p24
Presents information on InSync, a cardiac resynchronization therapy that have been developed by Medtronic to treat congestive heart failure. Projected market for heart failure device by 2006; Features of the InSync system; Estimated cost of treating heart failure in the U.S.
- Insulin-Like Growth Factor I: An Attractive Option for Chronic Heart Failure? Donath, M.Y.; Zapf, J. // Drugs & Aging;1999, Vol. 15 Issue 4, p251
Chronic congestive heart failure is a syndrome with a poor prognosis. Currently, the only therapy providing the possibility of long term survival is heart transplantation. Therefore, new therapeutic strategies continue to be investigated. One such new approach may be the application of...
- Standardized Hawthorn Extract WS 1442 - Herbal Approach to Congestive Heart Failure. Brown, Donald J. // Townsend Letter for Doctors & Patients;Aug/Sep2002, Issue 229/230, p128
Reports on the development of a standardized extract of hawthorn leaves and flowers in Europe that has led to a novel approach to the treatment of congestive heart failure. Active constituents and mechanism of action; Side effects and contraindications.